<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221230</url>
  </required_header>
  <id_info>
    <org_study_id>K2-MDD-201</org_study_id>
    <nct_id>NCT04221230</nct_id>
  </id_info>
  <brief_title>Study in Major Depressive Disorder With BTRX-335140 vs Placebo</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 Versus Placebo in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackThorn Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlackThorn Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A proof of concept (POC) study evaluating the impact of BTRX-335140 relative to placebo on&#xD;
      symptoms of major depressive disorder (MDD) in adult subjects with MDD and symptoms of&#xD;
      anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17&#xD;
      Scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD-17)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in baseline to Week 8 on the HAMD-17 score; Minimum 0, Maximum 52; Higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The CGI-I is a clinician rating of how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The SHAPS is a self-report 14-item, instrument, developed for the assessment of hedonic capacity. Participants score whether they experience pleasure in performing a list of activities or experiences. Participants can rate the answers as &quot;definitely/strongly agree&quot;, &quot;agree&quot;, &quot;disagree&quot; or &quot;strongly disagree&quot;. &quot;Definitely agree&quot; will be rated 1, &quot;Agree&quot; will be rated 2, &quot;Disagree&quot; will be rated 3, and &quot;Definitely disagree&quot; will be rated 4. The participant's item responses are summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicates higher levels of current anhedonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hospital Anxiety and Depression Scale (HADS) subscales (ie, anxiety subscale [HADS-A] and depression subscale [HADS-D]) scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire with 2 subscales: anxiety and depression. Each item is rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression with higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The HAM-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree) with a total score range of 0 to 52 where higher score indicates greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sheehan Disability Scale (SDS) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Sheehan Disability Scale (SDS) is a 3-item self-report questionnaire used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Assessment of safety through the occurrence of TEAEs, SAEs, and adverse events of special interest (AESIs)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in vital signs measurements, body weights, body mass index (BMI), clinical laboratory test results, C SSRS scores, Clinical Opiate Withdrawal Scale (COWS) scores; physical examination findings, ECG results, and ophthalmologic examination findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>BTRX-335140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTRX-335140</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTRX-335140</intervention_name>
    <description>Active Drug</description>
    <arm_group_label>BTRX-335140</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are eligible to be included in the study only if they meet all the following&#xD;
        criteria:&#xD;
&#xD;
          1. Are adult men or women 18 to 65 years of age (inclusive) at informed consent&#xD;
&#xD;
          2. Have a primary DSM-5 diagnosis of MDD, with prominent symptoms of anhedonia confirmed&#xD;
             by Structured Clinical Interview for DSM-5 Disorders, Clinical Trials Version&#xD;
             (SCID-5-CT)&#xD;
&#xD;
               1. The current episode must have started at least 3 weeks prior to screening but no&#xD;
                  more than 12 months before the screening visit.&#xD;
&#xD;
               2. Have not failed 2 or more courses of antidepressant treatment in the current&#xD;
                  episode&#xD;
&#xD;
               3. No more than a 3-point change in HAMD 17 between screening and baseline&#xD;
&#xD;
               4. Have sufficient history or an independent report to confirm that symptoms are&#xD;
                  causing functional impairment or clinically significant distress&#xD;
&#xD;
          3. Meet the blinded rule list based on clinical scale criteria&#xD;
&#xD;
          4. Body mass index (BMI) between 18-40 kg/m2 (inclusive)&#xD;
&#xD;
          5. Medically stable (in the opinion of the investigator and Sponsor/Sponsors delegate)&#xD;
             based on medical history, vital signs, clinical laboratory tests, and 12-lead&#xD;
             electrocardiogram (ECG) performed at screening and baseline&#xD;
&#xD;
          6. Agree to the following birth control:&#xD;
&#xD;
               1. Nonvasectomized men must agree to use a condom with spermicide, if sexually&#xD;
                  active during the study, until 90 days after the last dose of study drug&#xD;
                  administration. No restrictions are required for a vasectomized man, provided his&#xD;
                  vasectomy was performed 4 months or more prior to the first dose of study drug. A&#xD;
                  man who has been vasectomized less than 4 months prior to the first dose of study&#xD;
                  drug must follow the same restrictions as a nonvasectomized man. Additionally,&#xD;
                  men must refrain from sperm donation during study treatment and for at least 90&#xD;
                  days following the last dose of study drug.&#xD;
&#xD;
               2. Women of child-bearing potential (women not surgically sterilized and between&#xD;
                  menarche and 2 years postmenopausal) must have a negative serum pregnancy test at&#xD;
                  screening and a negative urine pregnancy test at enrollment and agree to use&#xD;
                  reliable birth control (eg, oral contraceptives or NorplantÂ®; a reliable double&#xD;
                  barrier method of birth control [diaphragms with contraceptive jelly; cervical&#xD;
                  caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine&#xD;
                  devices; partner with vasectomy; or abstinence) during the study and for 10 days&#xD;
                  following the last dose of the study drug (BTRX-335140 or placebo). Women will be&#xD;
                  considered surgically sterile, if they have had tubal ligation, bilateral&#xD;
                  salpingo oophorectomy, or a hysterectomy.&#xD;
&#xD;
                  Note: Abstinence will be allowed if, in the investigator's judgement, it is&#xD;
                  determined that the subject is reliable, that abstinence is the preferred and&#xD;
                  usual lifestyle of the subject, and that abstinence will be continued for the&#xD;
                  duration of the study including the 10 days (women) or 90-day period (men)&#xD;
                  following last dose of study drug as noted above.&#xD;
&#xD;
               3. Or engaged exclusively in a non-heterosexual relationship&#xD;
&#xD;
          7. Willing and able to give written informed consent to participate&#xD;
&#xD;
          8. Able to understand and comply with instructions in English&#xD;
&#xD;
          9. Are judged by the investigator to be reliable and agree to keep all appointments for&#xD;
             clinic visits, tests, and procedures, including venipuncture, and examinations&#xD;
             required by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
          1. Have a history of any of the following DSM-5 disorders within the specified timeframe:&#xD;
&#xD;
               1. Currently or in the past year: diagnosis of personality disorder, attention&#xD;
                  deficit disorder/attention deficit hyperactivity disorder, anorexia nervosa, or&#xD;
                  bulimia nervosa. Subjects with comorbid generalized anxiety disorder, social&#xD;
                  anxiety disorder, or panic disorder for whom MDD is considered the primary&#xD;
                  diagnosis are not excluded.&#xD;
&#xD;
               2. Lifetime: diagnosis of bipolar 1 or 2, schizophrenia, obsessive compulsive&#xD;
                  disorder, or post-traumatic stress disorder&#xD;
&#xD;
          2. Have a history of substance or alcohol use disorder (AUD), per DSM-5 criteria, within&#xD;
             the past year&#xD;
&#xD;
          3. Are actively suicidal (eg, any suicide attempts within the past 12 months) or are at&#xD;
             serious suicidal risk as indicated by any current suicidal intent, including a plan,&#xD;
             as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) (score of &quot;YES&quot; on&#xD;
             suicidal ideations item 4 or 5 within 3 months prior to Visit 1 [Screening]) and/or&#xD;
             based on clinical evaluation by the investigator; or are homicidal, in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          4. Have a history or signs of Cushing's disease, Addison's Disease, primary amenorrhea or&#xD;
             other evidence of significant disorders of the hypothalamus-pituitary-adrenal axis&#xD;
&#xD;
          5. Have any other clinically significant medical or psychiatric condition or circumstance&#xD;
             prior to randomization that, in the opinion of the investigator, or Sponsor could&#xD;
             affect subject safety, preclude evaluation of response, interfere with the ability to&#xD;
             comply with study procedures, or prohibit completion of the study, such as acute&#xD;
             stress disorder, adjustment disorder, impulse control disorder, uncontrolled diabetes&#xD;
             mellitus, renal or hepatic impairment, coronary artery disease, evidence of&#xD;
             significant active cardiac, respiratory, or hematologic disease, cancer with &lt;5 year&#xD;
             remission (basal cell carcinoma is not excluded), chronic pain, fibromyalgia, gastric&#xD;
             bypass, lap band placement, or any other significant gastrointestinal condition&#xD;
&#xD;
          6. Have had prior seizures (other than remote history of childhood febrile seizure) or&#xD;
             other condition that would place the subject at increased risk of seizures or is&#xD;
             taking anticonvulsants for seizure control&#xD;
&#xD;
          7. Have a history of serious head injury (eg, skull fracture, cerebral contusion, or&#xD;
             trauma resulting in prolonged unconsciousness), intracranial neoplasm, or hemorrhage&#xD;
&#xD;
          8. Have ever had electroconvulsive treatment, vagal nerve stimulation, or treatment with&#xD;
             ketamine or esketamine for MDD&#xD;
&#xD;
          9. Have initiated transcranial magnetic stimulation, psychotherapy (such as Cognitive&#xD;
             Behavioral Therapy) or have had a change in psychotherapy, or other non-drug therapies&#xD;
             (such as acupuncture or hypnosis) within 4 weeks prior to Visit 1 (Screening) or at&#xD;
             any time during the acute phase of the study&#xD;
&#xD;
         10. Have a visual or physical motor impairment that could interfere with subject's ability&#xD;
             to perform study assessments, as assessed by the investigator&#xD;
&#xD;
         11. Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels â¥2 x&#xD;
             upper limit of normal (ULN) or a bilirubin level 1.5 x ULN unless due to a documented&#xD;
             history of Gilbert's syndrome&#xD;
&#xD;
         12. Estimated glomerular filtration rate (eGFR) â¤60 mL/min/1.73m2 as calculated by the&#xD;
             Chronic Kidney Disease Epidemiology Collaboration [CKD EPI] 2009 creatinine equation&#xD;
             at Visit 1 (Screening)&#xD;
&#xD;
         13. Positive hepatitis C virus (HCV) antibody (Ab), hepatitis B surface antigen (HBs Ag),&#xD;
             hepatitis A virus (HAV) IgM antibody (HAV-Ab [IgM]) or human immunodeficiency virus&#xD;
             (HIV) test at Visit 1 (Screening)&#xD;
&#xD;
         14. Have a thyroid-stimulating hormone (TSH) level of &lt;0.9 x lower limit of normal (LLN)&#xD;
             or &gt;1.2 x ULN on or off stable treatment for hyperthyroidism or hypothyroidism; if TSH&#xD;
             is abnormal, evaluate reflex Free T3 and Free T4. If reflex testing is normal, the&#xD;
             assessment of normal thyroid function will be determined based on the judgement of the&#xD;
             investigator, following discussion with the medical monitor.&#xD;
&#xD;
         15. Have any other clinically significant abnormalities (significant would include&#xD;
             laboratory deviations requiring acute medical intervention or further medical&#xD;
             evaluation) in laboratory results at screening, including clinical chemistries,&#xD;
             hematology, and urinalysis, and any clinical information that, in the judgment of the&#xD;
             investigator or Sponsor, should preclude a subject's participation at study entry&#xD;
&#xD;
         16. Exclusionary ECG abnormalities obtained at Visit 1 (Screening) or Visit 2 (Baseline)&#xD;
             are QT interval corrected using Fridericia's formula (QTcF) &gt;450 msec in males or &gt;470&#xD;
             msec in females, complete bundle branch block, evidence of myocardial infarction or&#xD;
             ischemia, and predominantly nonsinus conducted rhythms. Other abnormalities can be&#xD;
             exclusionary at the discretion of the principal investigator or medical monitor. See&#xD;
             Section 6.3.5 of protocol for guidance on ECG interpretations.&#xD;
&#xD;
         17. Have a positive urine drug screen for amphetamines, barbiturates, cocaine, methadone,&#xD;
             opioids, propoxyphene, tetrahydrocannabinol (THC), phencyclidine, or a positive blood&#xD;
             alcohol level assessed by breathalyzer at Visit 1 (Screening) and Visit 2 (Baseline).&#xD;
             For occasional (1 to 2 times per month maximum) cannabis users only, 1 retest is&#xD;
             allowed and subject must agree to abstain from use for the duration of the study; a&#xD;
             positive second test is exclusionary.&#xD;
&#xD;
         18. Have any use, by history, of Salvinorin A&#xD;
&#xD;
         19. Use of the following concomitant medications (contact the Sponsor-designated medical&#xD;
             monitor to determine eligibility when in doubt):&#xD;
&#xD;
               1. Psychoactive medication including stimulants, benzodiazepines and anxiolytics,&#xD;
                  oral antipsychotics, mood stabilizers/anticonvulsants (carbamazepine,&#xD;
                  lamotrigine, etc.), lithium, antidepressants, S adenosylmethionine, melatonin,&#xD;
                  agomelatine, and hypnotics/sedatives within 5 half-lives or 14 days (whichever is&#xD;
                  longer) of Visit 2 (Baseline)&#xD;
&#xD;
               2. Fluoxetine and irreversible monoamine oxidase inhibitors within 4 weeks of Visit&#xD;
                  2 (Baseline) depot antipsychotics within 2 months of Visit 2 (Baseline)&#xD;
&#xD;
               3. Opioid agonists and antagonists&#xD;
&#xD;
         20. Are currently taking or have taken within 5 half-lives of Visit 2 (Baseline) any&#xD;
             medications or supplements that are moderate or strong inhibitors or inducers of&#xD;
             cytochrome P450 (CYP) 3A4 (non-comprehensive list in protocol), on a diet likely to&#xD;
             modulate CYP3A4 activity (eg, food/juice of grapefruit, Seville oranges), or are&#xD;
             taking substrates of P-glycoprotein (P gp) with narrow therapeutic windows (eg,&#xD;
             digoxin).&#xD;
&#xD;
         21. Are women who are either pregnant or breastfeeding&#xD;
&#xD;
         22. Have participated (received study treatment) in a clinical study or any other type of&#xD;
             medical research judged by the investigator or Sponsor to be scientifically or&#xD;
             medically incompatible with this study within 30 days prior to Visit 1 (Screening).&#xD;
             Contact the Sponsor-designated medical monitor to determine eligibility when in doubt.&#xD;
&#xD;
         23. Have participated in multiple interventional clinical studies, such that, in the&#xD;
             opinion of the investigator, the subject is not a suitable candidate for participation&#xD;
&#xD;
         24. Have previously completed or withdrawn from this study or any other study&#xD;
             investigating BTRX 335140&#xD;
&#xD;
         25. Are investigator site personnel directly affiliated with this study, and/or their&#xD;
             immediate families. Immediate family is defined as a spouse, parent, child, or&#xD;
             sibling, whether biological or legally adopted.&#xD;
&#xD;
         26. Are employees of the Sponsor or are employees of any third-party organizations (TPOs)&#xD;
             (eg, laboratory staff, study vendors and transportation providers) involved in study&#xD;
             who require exclusion of their employees&#xD;
&#xD;
         27. Has any of the following: 1) useful vision in only 1 eye from a pre-existing&#xD;
             ophthalmic disease or amblyopia; 2) a corneal transplant in either eye; 3) corneal&#xD;
             dystrophy or family history of corneal dystrophy; 4) severe dry eye syndrome&#xD;
             [keratitis sicca]; 5) will not or cannot cooperate with ophthalmic examination&#xD;
             requiring pupillary dilation (includes history of severe adverse reaction to mydriatic&#xD;
             agents or untreated narrow angle glaucoma). Note: The following ocular disorders are&#xD;
             allowed: cataracts, prior cataract surgery, glaucoma (narrow angle glaucoma is allowed&#xD;
             if definitively treated with laser peripheral iridectomy), macular degeneration, or&#xD;
             ocular changes associated with diabetes mellitus or multiple sclerosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Tiller, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>BlackThorn Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louis Wong</last_name>
    <phone>(415) 912-9482</phone>
    <email>Louis.Wong@BlackThornrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tausha Crawford</last_name>
      <phone>479-367-2688</phone>
      <email>tcrawford@pillarhc.com</email>
    </contact>
    <investigator>
      <last_name>Fayz Hudefi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atria Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Smith</last_name>
      <phone>501-353-1477</phone>
      <email>csmith@atriaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Prasad Padala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Knight</last_name>
      <phone>501-553-9987</phone>
      <phone_ext>108</phone_ext>
      <email>kknight@preferredresearchpartners.com</email>
    </contact>
    <investigator>
      <last_name>Paul Wylie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Orellana</last_name>
      <phone>562-748-4999</phone>
      <email>jenny.orellana@citrials.com</email>
    </contact>
    <investigator>
      <last_name>Diane Highum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Lark</last_name>
      <phone>424-227-8127</phone>
      <email>hannah.lark@prosciencerg.com</email>
    </contact>
    <investigator>
      <last_name>Marina Bussel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Lendennie</last_name>
      <phone>714-799-7799</phone>
      <phone_ext>1887</phone_ext>
      <email>alyssalendennie@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>Haig Goenjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialist, LLC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Sandoval</last_name>
      <phone>888-255-5798</phone>
      <email>alfonso@brstrials.com</email>
    </contact>
    <investigator>
      <last_name>Jesse Carr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evely Rendon</last_name>
      <phone>562-548-8500</phone>
      <email>erendon@allianceforresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Hilliard</last_name>
      <phone>562-548-8500</phone>
      <email>ahilliard@allianceforresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Zarate-Rowell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violet Navarrette</last_name>
      <phone>951-300-4924</phone>
    </contact>
    <investigator>
      <last_name>Grace Morehart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lumos Clinical Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidwath Kashyap</last_name>
      <phone>415-741-6103</phone>
      <email>vkashyap@lumosclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sarbani Maitra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ann</last_name>
      <phone>714-979-4101</phone>
      <email>john.ann@citrials.com</email>
    </contact>
    <investigator>
      <last_name>Robert Bota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Gursky</last_name>
      <phone>818-788-0746</phone>
      <email>ellen@smrionline.com</email>
    </contact>
    <investigator>
      <last_name>Jose Martin Itzcovich-Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winnie Alonzo</last_name>
      <email>winniealonzo@cnstrial.com</email>
    </contact>
    <contact_backup>
      <last_name>Rey Levi Calisin</last_name>
      <phone>310- 523-4200</phone>
      <email>Reylevicalisin@cnstrial.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lara Shirikjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Management Group LLC</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleesha Browning</last_name>
      <phone>909-920-3000</phone>
      <email>abrowning@pcrmg.com</email>
    </contact>
    <investigator>
      <last_name>Sameer Hassamal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research Specialists</name>
      <address>
        <city>Fernandina Beach</city>
        <state>Florida</state>
        <zip>32034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Groth</last_name>
      <phone>561-207-0434</phone>
      <email>jgroth@ccrsjax.com</email>
    </contact>
    <contact_backup>
      <last_name>Lawrence Whiting</last_name>
      <phone>904-468-3125</phone>
      <email>lwhiting@ccrsjax.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carly Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Gellers</last_name>
      <phone>904-281-5757</phone>
      <email>bgellers@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>John Mark Joyce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Broward Outpatient Clinic</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kadian Watson</last_name>
      <phone>954-990-6326</phone>
      <phone_ext>5397</phone_ext>
      <email>kwatson@segaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Rishi Kakar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Lakes Medical Research Outpatient Division</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessmin Richani</last_name>
      <phone>305-722-8444</phone>
      <phone_ext>2244</phone_ext>
      <email>jrichani@segaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Olga Lapeyra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>K2 Medical Research, LLC.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Stanton</last_name>
      <phone>407-590-9400</phone>
      <email>sean.stanton@k2med.com</email>
    </contact>
    <investigator>
      <last_name>Brandon Lenox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Littlejohn</last_name>
      <phone>407-425-5100</phone>
      <email>blittlejohn@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Felipe Suplicy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Headlands Research Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kori Garrison</last_name>
      <phone>941-529-8978</phone>
      <email>kori.garrison@headlandsresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Scheiderer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Raufman</last_name>
      <phone>404-255-6005</phone>
      <email>bonnie.raufman@globalaes.com</email>
    </contact>
    <investigator>
      <last_name>Bethany Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lerman</last_name>
      <phone>404-881-5800</phone>
      <email>mlerman@acmr.org</email>
    </contact>
    <investigator>
      <last_name>Mark Lerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Behavioral Research, LLC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ada Spahija</last_name>
      <phone>770-458-0447</phone>
      <phone_ext>Option 2</phone_ext>
      <email>ada@gapsychiatry.com</email>
    </contact>
    <investigator>
      <last_name>Suneel Katragadda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abel Beck</last_name>
      <phone>404-537-1281</phone>
      <email>abel.beck@iresearchatlanta.com</email>
    </contact>
    <investigator>
      <last_name>Saundra Maass-Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macedo Mariana</last_name>
      <phone>702-527-7401</phone>
      <email>mmacedo@altearesearch.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Kunovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolph McClain</last_name>
      <phone>856-753-7335</phone>
      <email>rmcclain@hritrials.com</email>
    </contact>
    <investigator>
      <last_name>Steve Glass</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials, LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natia Adamia</last_name>
      <phone>718-444-7774</phone>
      <phone_ext>121</phone_ext>
      <email>natia.adamia@iclinicaltrials.net</email>
    </contact>
    <contact_backup>
      <last_name>Bella Yevseva</last_name>
      <phone>718-444-7774</phone>
      <phone_ext>114</phone_ext>
      <email>bella.yevseva@iclinicaltrials.net</email>
    </contact_backup>
    <investigator>
      <last_name>Inna Yuryev-Golger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research - Queens</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Turrigiano</last_name>
      <phone>718-969-3005</phone>
      <email>eva.turrigiano@globalaes.com</email>
    </contact>
    <investigator>
      <last_name>Aggy Vallanat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Behavioral Medicine, PLLC.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozod Shams</last_name>
      <phone>646-678-4073</phone>
      <email>ozod@nymbm.com</email>
    </contact>
    <investigator>
      <last_name>Judith Joseph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanoelani-Lindsey Lanias</last_name>
      <phone>585-241-9670</phone>
      <email>Slanias@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Atkinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono</last_name>
      <phone>718-317-5522</phone>
      <phone_ext>301</phone_ext>
      <email>mdibuono@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mark DiBuono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hoke</last_name>
      <phone>937-424-1050</phone>
      <email>lhoke@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Otto Dueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marci Early</last_name>
      <email>mearly@soonerclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Amy Smith</last_name>
      <email>asmith@soonerclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Veronique Sebastian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Presley</last_name>
      <phone>901-843-1045</phone>
      <email>rpresley@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Valerie Arnold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grayline Research Center</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Vanderveen</last_name>
      <phone>801-803-6414</phone>
      <email>Ckenley@alpine-research.com</email>
    </contact>
    <investigator>
      <last_name>Jeremy Chiles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

